EICHORCondition: Lupus Erythematosus, Systemic · Sponsor: AstraZeneca
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study aims to describe clinical outcomes, with focus on remission, achieved with use of anifrolumab participants with SLE on standard-of-care (as recommended by 2025 China SLE guidelines). Further, it aims to describe outcomes alongside a systematic approach to glucocorticoid (GC) tapering, in terms of effectively minimising GC use, as well as discontinuing GC use, thereby reducing GC exposure.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Beijing, China | — |
| Research Site | Beijing, China | — |
| Research Site | Beijing, China | — |
| Research Site | Bengbu, China | — |
| Research Site | Changchun, China | — |
| Research Site | Changchun, China | — |
| Research Site | Changsha, China | — |
| Research Site | Chengdu, China | — |
| Research Site | Guangdong Province, China | — |
| Research Site | Guangzhou, China | — |
| Research Site | Guangzhou, China | — |
| Research Site | Guangzhou, China | — |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07751848